Syncope Predicts the Outcome of Cardiomyopathy Patients. Analysis of the SCD-HeFT Study

Journal of the American College of Cardiology

Volumn 51, Issue 13, 2008, Pages 1277-1282

  Olshansky, Brian ^a   Poole, Jeanne E ^b   Johnson, George ^e   Anderson, Jill ^e   Hellkamp, Anne S ^d   Packer, Douglas ^c   Mark, Daniel B ^d   Lee, Kerry L ^d   Bardy, Gust H ^e  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MAYO CLINIC   (United States)

^d DUKE UNIVERSITY   (United States)

^e Seattle Institute for Cardiac Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASODILATOR AGENT; WARFARIN;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QRS COMPLEX; RECURRENT DISEASE; SUDDEN DEATH; SYNCOPE; UNIVARIATE ANALYSIS;

ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHIES; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HEALTH STATUS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK; RISK FACTORS; STROKE VOLUME; SYNCOPE; TIME FACTORS; TREATMENT OUTCOME;

EID: 40949088273     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.11.065     Document Type: Article

References (32)

1. Soteriades E.S., Evans J.C., Larson M.G., et al. Incidence and prognosis of syncope. N Engl J Med 347 (2002) 878-885
2. Kapoor W.N., and Hanusa B.H. Is syncope a risk factor for poor outcomes?. Comparison of patients with and without syncope. Am J Med 100 (1996) 646-655
3. Racco F., Sconocchini C., Alesi C., Zappelli L., and Pratillo G. Long-term follow-up after syncope. A group of 183 patients observed for 5 years. Minerva Cardioangiol 48 (2000) 69-78
4. Olshansky B., Hahn E.A., Hartz V.L., Prater S.P., and Mason J.W. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators. Am Heart J 137 (1999) 878-886
5. Steinberg J.S., Beckman K., Greene H.L., et al. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. Antiarrhythmics Versus Implantable Defibrillators. J Cardiovasc Electrophysiol 12 (2001) 996-1001
6. Militianu A., Salacata A., Seibert K., et al. Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope. J Cardiovasc Electrophysiol 8 (1997) 1087-1097
7. Menon V., Steinberg J.S., Akiyama T., Beckman K., Carillo L., and Kutalek S. Implantable cardioverter defibrillator discharge rates in patients with unexplained syncope, structural heart disease, and inducible ventricular tachycardia at electrophysiologic study. Clin Cardiol 23 (2000) 195-200
8. Andrews N.P., Fogel R.I., Pelargonio G., Evans J.J., and Prystowsky E.N. Implantable defibrillator event rates in patients with unexplained syncope and inducible sustained ventricular tachyarrhythmias: a comparison with patients known to have sustained ventricular tachycardia. J Am Coll Cardiol 34 (1999) 2023-2030
9. Link M.S., Costeas X.F., Griffith J.L., Colburn C.D., Estes III N.A., and Wang P.J. High incidence of appropriate implantable cardioverter-defibrillator therapy in patients with syncope of unknown etiology and inducible ventricular arrhythmias. J Am Coll Cardiol 29 (1997) 370-375
10. Middlekauff H.R., Stevenson W.G., Stevenson L.W., and Saxon L.A. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 21 (1993) 110-116
11. Fruhwald F.M., Eber B., Schumacher M., Zweiker R., Watzinger N., and Klein W.W. Syncope in dilated cardiomyopathy is a predictor of sudden cardiac death. Cardiology 87 (1996) 177-180
12. Knight B.P., Goyal R., Pelosi F., et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 33 (1999) 1964-1970
13. Martin T.P., Hanusa B.H., and Kapoor W.N. Risk stratification of patients with syncope. Ann Emerg Med 29 (1997) 459-466
14. Russo A.M., Verdino R., Schorr C., et al. Occurrence of implantable defibrillator events in patients with syncope and nonischemic dilated cardiomyopathy. Am J Cardiol 88 (2001) 1444-1446
15. Link M.S., Kim K.M., Homoud M.K., Estes III N.A., and Wang P.J. Long-term outcome of patients with syncope associated with coronary artery disease and a nondiagnostic electrophysiologic evaluation. Am J Cardiol 83 (1999) 1334-1337
16. Fonarow G.C., Feliciano Z., Boyle N.G., et al. Improved survival in patients with nonischemic advanced heart failure and syncope treated with an implantable cardioverter-defibrillator. Am J Cardiol 85 (2000) 981-985
17. Sanchez J.M., Katsiyiannis W.T., Gage B.F., et al. Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm 2 (2005) 367-373
18. Nazarian S., Maisel W.H., Miles J.S., Tsang S., Stevenson L.W., and Stevenson W.G. Impact of implantable cardioverter defibrillators on survival and recurrent hospitalization in advanced heart failure. Am Heart J 150 (2005) 955-960
19. LeLorier P., Krahn A.D., Klein G.J., Yee R., and Skanes A.C. Comparison of patients with syncope with left ventricular dysfunction and negative electrophysiologic testing to cardiac arrest survivors and patients with syncope and preserved left ventricular function and impact of an implantable defibrillator. Am J Cardiol 90 (2002) 77-79
20. Cappato R., Negroni S., Bentivegna S., et al. Role of implantable cardioverter defibrillators in dilated cardiomyopathy. J Cardiovasc Electrophysiol 13 (2002) S106-S109
21. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
22. Packer D.L., Bernstein R., Wood F., et al. Impact of amiodarone versus implantable cardioverter defibrillator therapy on the mode of death in congestive heart failure patients in the SCD-HeFT trial. (abstr). Heart Rhythm 2 Suppl 1 (2005) S38-S39
23. Poole J.E., Johnson G., Callans D.J., et al. Analysis of implantable defibrillator shock electrograms in the Sudden Cardiac Death-Heart Failure Trial. (abstr). Heart Rhythm 1 (2004) S178
24. Poole J.E., Johnson G.W., Hellkamp A.S., et al. Mortality after appropriate and inappropriate shocks in SCD-HeFT. (abstr). Heart Rhythm 13 Suppl 1 (2006) S40
25. Shen W.K., Decker W.W., Smars P.A., et al. Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. Circulation 110 (2004) 3636-3645
26. Middlekauff H.R., Stevenson W.G., and Saxon L.A. Prognosis after syncope: impact of left ventricular function. Am Heart J 125 (1993) 121-127
27. Kapoor W.N., Karpf M., Wieand S., Peterson J.R., and Levey G.S. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 309 (1983) 197-204
28. Goldschlager N., Epstein A.E., Grubb B.P., et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 163 (2003) 151-162
29. Olshansky B., Mazuz M., and Martins J.B. Significance of inducible tachycardia in patients with syncope of unknown origin: a long-term follow-up. J Am Coll Cardiol 5 (1985) 216-223
30. Pires L.A., May L.M., Ravi S., Parry J.T., Lal V.R., and Nino C.L. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators. Am J Cardiol 85 (2000) 725-728
31. Strickberger S.A., Benson D.W., Biaggioni I., et al. AHA/ACCF scientific statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. J Am Coll Cardiol 47 (2006) 473-484
32. Olatidoye A.G., Verroneau J., and Kluger J. Mechanisms of syncope in implantable cardioverter-defibrillator recipients who receive device therapies. Am J Cardiol 82 (1998) 1372-1376